Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥512.00 - ¥764.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.28B

Enterprise Value¥2.22B

Total Cash (Recent Filing)¥3.53B

Total Debt (Recent Filing)¥1.24B

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Aug 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-89.44

Shares Outstanding10,092,100

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue RecoveryA 253% YoY revenue rebound in 2025 signals meaningful demand recovery and product-market fit for Cyfuse's offerings. Sustained top-line growth supports scaling of operations, improves leverage of fixed R&D costs, and underpins medium-term prospects if margins can be stabilized.

Proprietary 3D Cell Assembly PlatformCyfuse's scaffold-free 3D cell assembly platform is a durable competitive asset in regenerative medicine, enabling instrument, consumable and service revenue streams. The specialized technology creates high switching costs for customers and supports long-term collaboration and licensing opportunities.

Manageable Leverage & Asset BaseLeverage under 0.5 with a sizable equity base and growing assets provides a financial cushion while the company invests in commercialization and R&D. This balance sheet strength reduces short-term insolvency risk and increases flexibility to access capital for durable growth initiatives.

Bears Say

Severe UnprofitabilityExtremely large negative operating and net margins indicate a cost structure that is not yet scalable. Persistent deep losses erode equity over time, make self-sustaining growth unlikely without structural cost reduction or material margin improvement, and raise execution risk.

Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external funding to sustain operations and commercialization. Continued cash burn constrains investment flexibility, increases dilution/financing needs, and elevates risk if revenue growth or margins slip.

Rising Debt & Financing RiskDebt increased meaningfully year-over-year, raising refinancing and interest-service risk while the company remains unprofitable. Growing leverage amid cash losses heightens the chance of more dilutive or costly financing, pressuring long-term capital structure stability.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥512.00 and its highest was ¥764.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.28B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 14, 2026 which is in 18 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on May 15, 2026. The company reported -¥22.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.56.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,092,100 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥22.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.622%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.